Research on cell senescence and immortalisation of murine embryonic fibroblasts (MEFs) has revealed important clues about genetic control of senescence in humans. To investigate senescence and genetic alterations in the p53 pathway that lead to senescence bypass in culture, we compared the behaviour of MEFs from wild-type (WT) mice with MEFs from Hupki mice, which harbour a humanized p53 gene. We found that humanising the p53 gene in mice preserved major features of the MEF senescence/immortalisation process. In both genotypes, a significant proportion of spontaneously arising cell lines had sustained either a p53 point mutation, or p19/ARF biallelic deletion. The p53 mutations selected for during Hupki MEF immortalisation have been found in human tumours and are classified in the yeast transactivation assay as transcriptionally defunct, suggesting that disabling this component of p53 activity is crucial in senescence bypass. Surprisingly, in spontaneously immortalised cell lines from both WT and Hupki MEFs, the predominant type of p53 mutation was a G to C transversion, rather than the G to T substitutions expected from the raised oxygen levels characteristic of standard culture conditions. Over half of the cell lines did not reveal evidence of p53 mutation or loss of p19/ARF, and retained a robust wild-type p53 response to DNA damage, supporting the inference from senescence bypass screens that alternative genetic routes to immortalisation occur.
Research on cell senescence and immortalisation of murine embryonic fibroblasts (MEFs) has revealed important clues about genetic control of senescence in humans. To investigate senescence and genetic alterations in the p53 pathway that lead to senescence bypass in culture, we compared the behaviour of MEFs from wild-type (WT) mice with MEFs from Hupki mice, which harbour a humanized p53 gene. We found that humanising the p53 gene in mice preserved major features of the MEF senescence/immortalisation process. In both genotypes, a significant proportion of spontaneously arising cell lines had sustained either a p53 point mutation, or p19/ARF biallelic deletion. The p53 mutations selected for during Hupki MEF immortalisation have been found in human tumours and are classified in the yeast transactivation assay as transcriptionally defunct, suggesting that disabling this component of p53 activity is crucial in senescence bypass. Surprisingly, in spontaneously immortalised cell lines from both WT and Hupki MEFs, the predominant type of p53 mutation was a G to C transversion, rather than the G to T substitutions expected from the raised oxygen levels characteristic of standard culture conditions. Over half of the cell lines did not reveal evidence of p53 mutation or loss of p19/ARF, and retained a robust wild-type p53 response to DNA damage, supporting the inference from senescence bypass screens that alternative genetic routes to immortalisation occur.
Cellular senescence is an important defence against tumour development, but it also plays a role in ageing and is a barrier to the successful reprogramming of somatic cells to pluripotency (1) (2) (3) . Senescence may be triggered by a variety of events, including DNA damage, expression of oncogenes, telomere shortening, and derepression of the ARF locus (4) . Whilst the evasion of senescence can have disastrous consequences for tumour chemotherapy (5, 6) , blocking senescence has been the key to recent success in generating pluripotent cells (iPS) from fibroblasts, bringing the promise of therapeutic use for iPS a step closer (7) . Understanding the ways in which cells are able to bypass senescence is thus relevant to the causes and treatment of cancer at multiple levels.
Mouse embryonic fibroblasts (MEFs) are a classic model system for studying senescence. Early ground-breaking studies established the importance of inactivation of the p53/p19ARF pathway in the immortalisation of MEFs (8) (9) (10) (11) More recently, high throughput screening methods have been used to investigate senescence rescue in MEFs and these have shown that disturbances in other components of the p53/Rb/AKT suppressor networks may conspire to prevent permanent growth arrest (12) (13) (14) (15) .
Immortalisation of human cells in culture is more complex than for MEFs. Disruption of the p53/p14ARF pathway (which corresponds to mouse p53/p19ARF) remains essential, but in addition, disruption of the Rb/p16 arm of the tumour suppressor node is necessary, together with a halt in telomere attrition during replication (16) . Despite this added complexity in human cells, several key aspects of cellular senescence have been retained in evolution and are at work in both mice and humans, thus studies in mouse models can provide essential clues to the molecular events in human cells.
We have produced human p53 knock in (Hupki) mouse strains to investigate p53 biology and tumour suppressor gene mutations (17, 18) . Hupki cells from the prototype Hupki strain retain wild-type p53 activity, including DNAdamage induced apoptosis and transcriptional activation of p53 responsive genes in response to stress, and Hupki mice are not tumour-prone (19, 20) . The model allows the extensive literature on MEF senescence bypass to be linked to specific alterations in human p53 that allow senescence bypass. Here we show that fibroblasts from mice with the humanised p53 gene behave like fibroblasts from normal (wild-type) mice during stressassociated senescence and spontaneous immortalisation in culture. We then demonstrate that mutations in human p53 sequences arising during spontaneous immortalisation of the fibroblast cultures correspond to human cancer p53 mutations known to be deficient in transcriptional activity. Unexpectedly, many of the p53 sequence changes selected for in senescence bypass are G:C to C:G transversions. We also found that a substantial fraction of MEF cell lines has apparently achieved immortalisation by routes other than the two canonical p53 pathway defects (p53 mutation; p19 biallelic deletion) previously linked to the process.
Experimental procedures
Cell Culture. Primary murine embryonic fibroblasts from wild-type mice (Strain 129) and from Hupki (human p53 knock-in) mice were distributed into individual wells of 6-well culture dishes at ca. 2 x 10 5 cells/well in DMEM supplemented with 10 % FCS. Each culture was passaged at 1:2 to 1:4 dilution when confluent. During the senescent, slow-tonon-growing phases of culturing (typically passage 4-7), medium was replaced at least once per week. Post-senescent cultures that had resumed growth were passaged at higher dilutions (1:6 to 1:10) before freezing in DMSO for long-term storage. The embryos used for preparation of 13.5 day old Hupki embryonic fibroblasts were heterozygous for the codon 72 polymorphism (obtained from crossing homozygous codon 72 arg/arg mice with codon 72 pro/pro mice) (21, 22) . Cultures were maintained under standard culture conditions (37ºC, 5% CO 2 in a humidified atmosphere).
Reactive oxygen species (ROS) measurements (23) . Cellular ROS levels were assessed by staining with the ROSsensitive dye, DCF-DA (Sigma D6883). Cells at p. 3 and p. 5 were seeded in triplicate at 2x10 5 cells per well in 6 well plates. After 48 hours, medium was removed, and replaced with 50µM DCF-DA in prewarmed Krebs-Ringer buffer (110 mM NaCl, 2.6 mM KCl, 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 , 11 mM glucose, pH7.4). Cells were protected from light, and incubated for 15 minutes under standard culture conditions to allow uptake of the dye. Cells were then either treated with the indicated concentrations of hydrogen peroxide, or left untreated, and incubated for a further 30 minutes. Cells were harvested by trypsinisation and fluorescence was measured on a FACSCalibur flow cytometer, gating on forward and side scatter, acquiring 10 000 events per sample. The average fluorescence was determined from the resulting histogram.
β-galactosidase staining of senescence cells (24) . Cells were seeded at 2.5x10 4 per well in 6 well plates, and allowed to grow for 5 days. They were then stained for senescence-associated β-galactosidase activity using the Sigma Senescence Cells Histochemical Staining Kit (CS0030), according to manufacturer's instructions. Cells were incubated with staining solution for 24 hours.
Single cell gel electrophoresis (alkaline comet assay) (25, 26) . DNA damage was measured by the single-cell alkaline comet assay. Primary WT and Hupki MEFs were treated as indicated in the figures. After treatment, cells were embedded in 1% low melting point agarose at a density 1 x 10 6 /ml and spread onto agarose coated slides. The cells were then immersed in ice-cold lysis buffer (10mM Tris-HCl, 2.5M NaCl, 100mM EDTA, 1% sodium N-lauryl sarcosinate, 1% Triton X-100, and 10% DMSO; pH 10) for 1 hour at 4ºC.
Slides were submerged in fresh cold enzyme buffer (40mM Hepes, 0.1M KCl, 0.5mM EDTA, 0.2mg/ml bovine serum albumin solution, pH 8, 4ºC) three times for 5 minutes and then treated with 50µl of FPG (formamidopyrimidine [fapy]-DNA glycosylase) enzyme or 50µl of enzyme buffer alone at 37ºC for 30 minutes. The slides were denatured in electrophoresis buffer (300mM NaOH and 1mM EDTA) for 40 minutes and electrophoresed at 25V, 300mA for 20 minutes. The slides were renatured in neutralisation buffer (0.4M TrisHCl; pH 7.5), and stained with 25µl ethidium bromide (25µg/ml). Comets were visualised using an Olympus BX41 microscope and analysed using Komet 5.5 software (Kinetic Imaging). 200 Comets (100 on each of 2 separate slides) were analysed per sample. p53 mutation screening. Genomic DNA was extracted from immortalized cell lines using standard procedures, and used as template for PCR amplification of murine p53 sequences (WT MEF cell lines) or human p53 sequences (Hupki MEF cell lines) using mouse-or human-specific intronic primers (Hupki p19/ARF deletion analysis. Individual exons were amplified from genomic DNA extracted from each cell line using 3 sets of murine CDKN2A-specific primers to amplify individually exon 1β (with primer p19Ex1-F, 5'-GTCACAGTGAGGCCGCCGCT-3' and primer p19Ex1-R, 5'-GGTCCAGGATTCCGGTGC-3'), exon 2 (with primer p19Ex2-F, 5'-TTAACAGCGGAGCTTCGTAC-3' and primer p19Ex2-R, 5'-TTTGGACCAACTATGCTCACC-3') ,and exon 3 (with primer p19Ex3-F 5'-GGAGACTCCAGATCCCATTAG-3' and p19Ex3-R 5'-ATGGCTGTTGTGACTGACG-3'). Amplicons were visualised on 1.5 % (exon 3) or 2 % (exon 1β and exon 2) agarose gels.
p19 promoter methylation analysis. The methylation status of the murine p19/ARF promoter was determined by sodium bisulfite modification of DNA, PCR amplification, and analysis of an approximately 300 bp CpG-rich promoter segment immediately upstream of exon 1β, as previously described (27) . An aliquot of genomic DNA (500ng) from each cell line was treated and purified with reagents from the EpiTect Bisulfite kit (Qiagen) according to manufacturer's instructions. Semi-nested PCR was performed with Platinum® Taq DNA polymerase (Invitrogen). Initial amplification of promoter sequences for 25 cycles was performed with primers 1FM (5'-GGGTGTAGTTATTGTTAGGGGG-3') and 1RM (5'-AAAAAACCCTCTCTTAAAATAAA-3'), and 2.4mM MgCl 2. Denaturation was at 94°C for 1 minute, annealing at 53°C for 35 s and extension at 72°C for 1 minute. The semi-nested second amplification step was performed with primers 1FM and 2RM (5'-ATCCTCACAATAACCAAAAACCTA-3'), 2.4mM MgCl 2, for 35 cycles (denaturation at 94°C for 1 minute, annealing at 63°C for 35 s and extension at 72°C for 1 minute plus 1 s/cycle). Amplification products were purified with a PCR product purification kit from Macherey-Nagel, and sequenced with primer 2RM by dideoxy fluorescent dye cycle sequencing.
Immunofluorescent staining. Cells were cultured on cover slips for 24 hours, then treated with or without 1µM adriamycin for 24 hours. Cells were fixed in 4% paraformaldehyde for 10 minutes and stored in PBS at 4ºC. Cells were permeabilized in 0.2% Triton X-100/PBS for 10 minutes at room temperature and blocked for 1 hour in 5% milk/PBS. Coverslips were incubated in CM-5 anti-p53 antiserum (Novocastra) (1:100 dilution in blocking buffer) overnight at 4ºC. Following PBS washes, secondary antibody (Donkey antirabbit AlexaFluor 488, Invitrogen; 1:500 dilution) and DAPI (1µg/ml) were applied for 1 hour before the coverslips were washed in PBS and mounted. Photomicrographs were taken using an inverted Olympus IX-70 wide field microscope.
Immunoblotting. Semi-confluent cultures were treated with 1µM adriamycin for the indicated periods. Treated cells were harvested and lysed in NP-40 buffer (50 mM Tris, pH8; 5mM EDTA, 150mM NaCl, and 0.5% NP-40) supplemented with protease inhibitors (1mM PMSF, 10ug/ml pepstatin A, 10 ug/ml aprotinin, and 5ug/ml leupeptin). Protein concentrations were determined by the method of Bradford (BioRad). 50 ug of protein was run on 10% SDS-PAGE gels (Invitrogen) and transferred overnight onto Immuno-Blot PVDF membrane (BioRad). Western blots were blocked and incubated in antibody in PBS/0.2% Tween-20/5% non-fat dry milk. Blots were incubated with antibody for 1 hour at room temperature, followed by washing in PBS/0.2% Tween-20 and incubation in peroxidase-conjugated secondary antibody (Southern Biotech) and chemiluminescence detection (NEN). Antibodies used were as follows: p53 (Novocastra, NCL-p53-CM5), pp53Ser15 (Cell Signalling #9284), MDM2 (BD Pharmingen), p21 (Santa Cruz sc471), p19ARF (BD Pharmingen) and GAPDH (Cell Signalling #2118).
Gene expression analysis. Cells were grown in 6-well plates, and left untreated, or treated with 1µM adriamycin for 8 hours. RNA was harvested using an RNeasy Mini Kit (Qiagen), and cDNA synthesised using a Cloned AMV first strand cDNA synthesis kit with random hexamer primers (Invitrogen). Real-time RT PCR was performed using Taqman® Gene Expression assays on ABI custom cards, using Taqman® Gene Expression Master Mix (Applied Biosystems) (full details of primerprobe sets are included in Supplementary  Table 1 ). Plates were run on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems).
Results

Senescence and immortalisation of MEF and HUF cultures.
Entry and escape from senescence. To compare the behaviour of explanted embryonic wild-type and Hupki mouse fibroblasts, we prepared 48 primary fibroblast cultures from 2 wild type murine embryos (E50, E55), and 48 cultures from 3 Hupki embryos (E22, E31, E32). Cultures were passaged when confluent until established lines were derived. All cultures at first ceased rapid proliferation and contained cells with flattened irregular morphologies within 2 weeks. After 4 weeks, most were at passage 6 or 7, whereas after 8 weeks, there was more variability in growth behaviour among the cultures ( Figure 1A ). No consistent difference between genotypes was noted, although WT MEF cultures entered senescence earlier than Hupki MEF cultures, and resumption of robust growth was more rapid in Hupki cultures ( Figure 1A ). This was confirmed by SA-β-galactosidase staining, with wild-type cells showing more positive cells at earlier passages, although by passage 7 both genotypes displayed similar levels of senescence as evaluated by SA-β-galactosidase staining and by culture morphology ( Figure 1B (28, 29) . We investigated the levels of ROS and DNA damage in primary WT and Hupki MEF cultures to determine whether replacing the murine p53 with a humanised p53 affects the cellular response to the oxidative stress of standard cell culture. ROS levels were evaluated by staining with the ROS-labile dye DCF-DA, while oxidative DNA damage was assessed using a modified alkaline comet assay with FPG. The susceptibility of WT and Hupki MEFs to further damage induced by hydrogen peroxide treatment was also assessed.
The basal ROS levels in WT MEFs were equivalent to those observed in Hupki MEFs, and these levels did not increase significantly from passage 3 to passage 5 ( Figure 2A ). DNA damage levels did not differ between genotypes, but did increase with passage number, and, as expected, with hydrogen peroxide treatment ( Figure 2B ). FPG excises 8-oxo-deoxyguanosine, a common product of oxidative DNA damage, producing a single strand break that is detected in the comet assay (30) . Treatment of slides with FPG increased the DNA damage detected, indicating that oxidative DNA damage is occurring in these cultures, although again, no difference was noted between the genotypes. At the 100 μM dose, the level of DNA damage induced was so high that the use of FPG to convert additional oxidised bases to strand breaks did not yield higher values, indicating that the system was saturated. At passage 6, the range of comet tail measurements widened dramatically, suggesting a heterogeneous cell population, probably of senescent and pre-or post-senescent (immortalising) fibroblasts within each culture, with differing levels of DNA damage.
Molecular changes in spontaneously immortalised cell lines.
p53 Mutations. A p53 missense mutation leading to accumulation of mutant p53 protein is the most common mechanism by which cells lose p53 pathway function and gain oncogenic properties during human tumourigenesis (31) (32) (33) . The importance of p53 inactivation during MEF senescence bypass is also well established (9, 11, (34) (35) (36) . To detect the presence of mutations and the precise sequence alterations in spontaneously immortalised WT and Hupki MEF cell lines, we performed direct mutation analysis by PCR amplification of exons 4-9 (encoding the polyproline and DNA binding domains of p53) and dideoxy sequencing of products using mouse or human sequence-specific primers as appropriate. Almost all missense p53 mutations in human tumours map to this approximately 200 bp segment of the coding sequence. In cell lines with no p53 mutations detected in this region, we proceeded to sequence the outlying coding exons, but did not detect any additional mutations. In MEFs, there has been little information on typical locations of p53 sequence changes associated with senescence bypass, and in human cells there is no equivalent experimental model in culture, thus no comparable information on senescence bypass-associated mutations exists.
The (37, 38) ).Unexpectedly, in both WT and Hupki spontaneously immortalised MEF cell lines, the most common base change we identified is a G:C to C:G transversion (10/12, 83 % in WT MEF; 33/64, 52% in Hupki MEFs) ( Table 1 ).
All but two of the mutations found in untreated, spontaneously immortalised cells have been observed in diverse human tumours (Table 1B; Supplementary Table 1) , although in some cases these mutations represent low frequency human tumour mutations. Various common human tumour p53 mutations ("signature" mutations) are associated with exposure to specific cancer causing agents. We have shown previously that "signature" human tumour p53 mutations can be induced in Hupki MEFs by exposing the primary cells to carcinogens, including benzo(a)pyrene and aristolochic acid (37, (39) (40) (41) . Hupki MEF mutations were detected in exons 4, 5, 6, 7 and 8, with a predominant hotspot at codon 135 (exon 5), and hotspots at codons 245 (exon 7), 273 (exon 7) and 281 (exon 8) (Figure 3) . The mutation data for the WT MEF cell lines, although limited in comparison, also reveals a cluster site in the region of exon 5 encompassing codon 135 (Table 1A ) .
The mutations found in Hupki MEFs are classified as defective in transcriptional transactivation activity by the comprehensive yeast functional study of Kato and colleagues (Table 1B,  Supplementary Table 1 )(42), indicating that loss of transactivation activity is a key feature of senescence bypass by p53 inactivation. Homozygous loss of p53 sequences was observed in both WT and Hupki cell lines, albeit rarely (2% or less of cell lines) ( Table 2) .
p19/ARF gene silencing by homozygous deletion. The p19/ARF protein has a non-permissive but critical role in p53-induced cellular senescence. When p19/ARF binds to Mdm2, a major negative regulator of p53, p53 is free to initiate the downstream events that culminate in permanent growth arrest (43) . Biallelic p19/ARF deletion was shown to be a key genetic route to senescence bypass in pioneering studies on the immortalisation of MEFs (10, 44) . We tested the 90 WT and Hupki MEF cell lines already sequenced for p53 mutations, for evidence of p19/ARF deletion by PCR. Although we detected more biallelic loss in WT MEF cell lines (8/47, 17%) than in Hupki MEF cell lines (2/43, 5%), the difference is not significant ( Table 2) . Consistent with the literature, p53 mutation and p19 deletion appear to be mutually exclusive genetic defects; we have not found both anomalies in the same cell line. Since exons 2 and 3 of the p19 locus are shared by both p16 and p19, although translated in different reading frames, loss of p16 as well as p19/ARF suppressor functions in the cell lines with no p19/ARF coding sequences can be inferred, although it is has been shown that loss of p19/ARF is the critical event (45) .
p19/ARF gene silencing by promoter methylation. We next asked whether loss of p19 function is achieved in some spontaneously immortalised cell lines by promoter methylation, considering that silencing of the suppressor occurs by this route in human cancers (46) (47) (48) , and given that silencing by biallelic loss of DNA at the p19/ARF locus occurred in over 10 % of the MEF cell lines we tested. DNA sequencing of CpG-rich promoter sequences following bisulfite modification of genomic DNA did not reveal evidence of cytosine methylation in any of the cell lines that would be consistent with silencing by this mechanism (Table 3) .
Wild-type p53 function is retained in cells without p53 mutation or p19/ARF biallelic deletion .
The p53 pathway is complex, and p53 function can be lost by many mechanisms other than the two canonical events described here (p53 mutation and p19/ARF deletion). For example, MDM2 amplification is frequently observed in human tumours, and is an established mechanism for p53 inactivation (43) . Mutations in the promoter of p53 can alter transcription levels, while alterations in post-translational modification can affect macromolecular interactions, conformation, and sub-cellular localisation.
In order to address the possibility that p53 function may be compromised by these other mechanisms, we proceeded to evaluate several key features of a robust, functioning p53 response.
The p53 literature amply documents that untreated cells with normal p53 have low levels of p53 and reactivity to anti-p53 antibody, whereas treatment with DNA damaging agents such as adriamycin causes rapid accumulation of wild-type p53 in the nucleus and strong staining with antibody. To confirm that p53 was induced following DNA damage, we examined the levels of p53 in untreated cells, and cells treated with adriamycin ( Figure 4A ). Levels of p53 in untreated cells were consistently low in the 17 cell lines with unmutated p53 in comparison to the high levels observed in cells carrying a mutant p53. In addition, treatment with adriamycin led to upregulation of p53, and a corresponding phosphorylation of p53 at serine15 ( Figure  4B) .
In human cancers, cytoplasmic sequestration is one of the mechanisms by which p53 can lose function without having sustained a mutation that alters structure of the protein (43, 49) . We thus asked whether the immortalised cell lines that did not harbour p53 mutations would reveal normal p53 subcellular localisation consistent with wild-type protein. We used immunofluorescence staining with an antibody against p53 to detect levels and location of p53 in untreated cells, and in cells treated with adriamycin ( Figure 5 ). As expected, cells with mutant p53 displayed strong immunoreactivity, regardless of the treatment conditions ( Figure 5 A and B) , while WT and Hupki MEF cell lines with unmutated p53 showed a typical p53 response, with nuclear accumulation ( Figure  5 C-F, and data not shown).
We did not observe levels of MDM2 in any of the wild-type cell lines examined ( Figure 4B ) that were elevated above amounts typical of primary cells, arguing against MDM2 gene amplification as a mechanism for p53 pathway dysfunction in the immortalisation process of the cell lines with unmutated p53. Although p19/ARF protein expression varied amongst the cell lines, it was detectable in all but one (E50/17; Figure 4B ), thus overall corroborating the results from PCR screening for biallelic deletion and the analysis of promoter methylation, which did not suggest silencing of this locus. Loss of p19/ARF expression in E50/17 may have occurred by a different mechanism.
Taken together, our findings suggest that upstream events leading to p53 stabilisation and activation following DNA damage are intact in almost all of the cell lines with unmutated p53.
We next turned our attention to downstream events in the p53 pathway. A key indicator of wild-type p53 status is the transactivation of p53 responsive genes. We used real-time PCR to determine the level of induction of multiple p53 target genes in a panel of wild-type cells of both genotypes following treatment with adriamycin. In all cases, cells with wild-type p53 showed induction of multiple p53 responsive genes, in contrast to the mutant and control p53 null cell lines, where at most only 3 genes were induced ( Figure 6 and Supplementary Table  2 ). In addition, immunoblot analysis indicates that p21 is upregulated in all wildtype cells after treatment ( Figure 4B ), but not in the p53 mutant cell lines.
Discussion
In this report we show that basic features of ROS-induced senescence and subsequent immortalisation of WT MEFs are retained in cells expressing a p53 protein with humanised polyproline and DNA binding domains (Hupki MEFs). While Hupki MEFs entered and exited senescence slightly earlier than WT MEFs, ROS levels and DNA damage levels in both cell types were similar at corresponding passages. As expected, and in agreement with early studies in genetically unmodified mice, p53 mutations and p19 deletions occurred in a significant proportion of spontaneously immortalised MEF cultures. The frequency of these events did not differ between WT MEFs and Hupki MEFs.
The most common p53 sequence changes in spontaneously immortalised MEF cell lines are missense mutations in the DNA binding-domain, just as is seen in human tumours (31, 32) . Unexpectedly, however, we observed a high frequency of G:C to C:G transversions in p53 in both immortalised MEFs and Hupki MEFs (Table 1) . Busuttil and co-workers showed that oxidative damage to DNA, a probable source of "spontaneous" mutations under standard culture conditions, induced predominantly G to T transversions in the lacZ reporter gene of transgenic MEFs (29) . G:C to A:T transitions resulting from the spontaneous deamination of 5-methylcytosine would be another expected hallmark sequence change, particularly when pro-mutagenic lesions from oxidative damage are not elevated. Base substitution patterns may vary depending on locus for several reasons, including sequence context, biological selection, DNA repair parameters, transcriptional activity, or other variables, which may contribute to differences in mutation patterns. One speculation regarding our findings in MEFs is that hotspot mutants particularly effective for bypassing senescence in culture (possibly C135W, from a TGC to TGG mutation, see Figure 1 ) are fortuitously derived from G to C transversions. This could be addressed by phenotypic study of the various p53 mutants generated to determine their effectiveness in outgrowing pre-senescent cultures. Curiously, although G:C to C:G transversions are not a common type of base substitution in cancer genes in humans (7-10 % of all substitutions), genome-wide unbiased re-sequencing of various tumour types has revealed an elevated G to C frequency in breast cancers (28 %), three times higher than in several other major cancers (7-10 %) , but the reasons for this are not known (50, 51) . Oddly, the unusually high G to C transversion frequency in breast tumour sequence variations is not observed in the p53 gene of breast tumours.
Previously, we have demonstrated that the Hupki system can be used to recapitulate mutation patterns induced by mutagenic carcinogens (37, (39) (40) (41) . The p53 mutations in Hupki MEF cell lines thus invite direct comparison with the in vivooccurring human tumour p53 mutations registered in databases (IARC p53 database : http://www-p53.iarc.fr/; p53 Knowledgebase : The TP53 Website database :
http://p53.free.fr/Database/p53_database.ht ml). We observed several key parallels between senescence bypass mutations and human tumour mutations: (a) the specific p53 mutations accompanying Hupki MEF senescence bypass in vitro are, like those in tumours, diverse; (b) the exact Hupki MEF sequence changes have been found in human tumours, and (c) as with most human tumour mutations, the yeast-based functional assay classifies most of the Hupki mutants in the "non-functional" category, that is, they are essentially devoid of transcriptional transactivation (TA) ability (42) . Obligatory loss of TA function in senescence bypassselected p53 mutants would support the findings from a recent study in knock-in mice harbouring a chimeric p53 protein lacking motifs for non-TA related functions. This elegant report demonstrated that p53-induced senescence of primary MEFs is dependent on the TA properties of p53 (52) .
Unexpectedly, regardless of genotype, more than half the immortalised cell lines we examined appeared to have overcome the initial senescence block by mechanisms other than disruption of the ARF/p53 pathway. In the spontaneously immortalised cell lines with unmutated p53, p53 and ARF proteins are present at normal levels, and p53 accumulates after DNA damage, with induction of multiple downstream targets of functional p53 (Figures 4, 5 and 6 ). In these cells dysfunction of other more distal genes in tumour suppressor network may be involved in senescence bypass (12) (13) (14) (15) . Alternatively, haploinsufficiency of p19/ARF or p53 in collaboration with modest expression changes in oncogenes or deregulation of the pathway from genomic rearrangements may have initially allowed senescence bypass in some cells and the emergence of immortalised cultures (53) (54) (55) .
The number of established cell cultures that harbour a p53 mutation can be influenced by the immortalisation protocol (56) , and possibly by mouse strain genetic background and growth medium/incubation conditions, which have varied from study to study in the literature. Our protocol allows cells to reach confluence prior to trypsinisation, which may have favoured cell lines which have acquired unlimited growth potential by non-canonical mechanisms.
Further study of cell lines with unmutated p53 sequences, a typical response to DNA damage and transcriptional transactivation of p53 target genes may reveal spontaneously occurring variant routes to senescence bypass. These alternate pathways could be of potential interest in efforts to achieve fibroblast reprogramming into iPS under circumstances that avoid the obvious dangers to cell integrity associated with harbouring mutant p53. TABLE 1A . p53 point mutations in spontaneously immortalised wild-type MEF cell lines. The p53 mutations observed in immortalised wild-type MEF cell lines are tabulated here, together with the equivalent codons in the human sequence (mouse and human p53 are highly similar in the DNA binding domain, but the C and N termini differ, and codon numbers are not equivalent). Rows that are highlighted in grey indicate that identical mutations have been observed in the two MEF cell types , while mutants indicated by an asterisk have been observed in the equivalent codons in Hupki cells. Frequency indicates the number of times the equivalent human mutation has been observed in the IARC p53 mutation database (v.R14), out of a total of 26597 reported mutations. The number of cell lines with either p53 mutations/deletions or p19 deletions as determined by PCR (p19) and sequencing (p53). *2 cell lines had 2 mutations.
TABLES
† Exons 2 and 3 of the CDKN2A locus encode tumour suppressor p16 as well as p19/ARF, in different reading frames.
‡ These genetic events were mutually exclusive: cell lines harboured either p53 mutations or had homozygous deletion at the CDKN2A locus, but not both. 
